BDNF and NT-3 may participate in neurodevelopment abnormalities. It is not clear if BDNF/NT-3 levels differ between schizophrenic and healthy individuals. Cognitive dysfunctions form the core of schizophrenia and may result from neurodevelopmental abnormalities.
Assessment of BDNF and NT-3 serum levels and cognitive performance in schizophrenia.
Study groups: 33 schizophrenic in-patients and 27 healthy subjects. Clinical symptoms: PANSS, HDRS, CDSS. Cognitive performance: Verbal Fluency Test (VFT), Color Word Interference Test (CWIT), Trail Making Test (TMT), Digit Symbol Substitution (DSYM), Luria Memory Words (LMW). BDNF and NT-3 levels were assessed using ELISA method.
PANSS, CDSS, HDRS scores (mean±SD): 49.2±16.2, 4.3±4.4, 10.1±7.6. Table 1 shows BDNF and NT-3 levels. Table 2 shows cognitive performance. Inter-variables correlations were found: BDNF-CDSS (r=−0.40, p=0.03) BDNF-HDRS (r=−0.51, p=0.003), NT-3-CWIT1 (r=0.32, p=0.01), NT-3-TMTA (r=0.36, p< 0.01), NT-3-LMW30 (r=−0.33, p=0.01).
Table 1 [BDNF (mean±SD) and NT-3 (mean±SD (median)) levels]Schizophrenia (n=33, I W/M 10/23, age 35.7±13.4)Control (n=27, W/M 17/10, age 36.1±9.4)PBDNF [ng/ml]21.30±5.6720.55±5.810.621NT-3 [pg/ml]114.78±261.78 (14.15)36.47±73.84 (13.80)0.703
|
| | Schizophrenia (n=33, I W/M 10/23, age 35.7±13.4) | Control (n=27, W/M 17/10, age 36.1±9.4) | P | | BDNF [ng/ml] | 21.30±5.67 | 20.55±5.81 | 0.621 | | NT-3 [pg/ml] | 114.78±261.78 (14.15) | 36.47±73.84 (13.80) | 0.703 |
|
Table 2 [Cognitive performance (mean±SD)]TestSchizophreniaControlPVFT Category 1/2/3 [words]17.4±6.1 /8.0±3.2/ 13.8±4.924.1±6.6/12.8±4.5/ 19.1±5.4<0.001CWIT Test 1/2 [seconds]28.8±10.7/82.0±33.921.3±3.0/51.8±14.5<0.001TMT A/B [seconds]47.8±29.4/ 120.0±65.625.1±9.1 /61.1±31.7<0.001DSYM [symbols]38.4±12.261.4±10.2<0.001LMW Trial 1st/Trial 10th/After 30 minutes [words]4.8±1.4/8.6±1.3/ 7.1±1.96.1±1.1 /9.8±0.4/ 9.1±1.0<0.001
|
| Test | Schizophrenia | Control | P | | VFT Category 1/2/3 [words] | 17.4±6.1 /8.0±3.2/ 13.8±4.9 | 24.1±6.6/12.8±4.5/ 19.1±5.4 | <0.001 | | CWIT Test 1/2 [seconds] | 28.8±10.7/82.0±33.9 | 21.3±3.0/51.8±14.5 | <0.001 | | TMT A/B [seconds] | 47.8±29.4/ 120.0±65.6 | 25.1±9.1 /61.1±31.7 | <0.001 | | DSYM [symbols] | 38.4±12.2 | 61.4±10.2 | <0.001 | | LMW Trial 1st/Trial 10th/After 30 minutes [words] | 4.8±1.4/8.6±1.3/ 7.1±1.9 | 6.1±1.1 /9.8±0.4/ 9.1±1.0 | <0.001 |
|
There were no differences in BDNF or NT-3 levels between groups. Schizophrenic patients had lower cognitive performance. An association between BDNF and depressive symptoms was confirmed.
Le texte complet de cet article est disponible en PDF.
© 2011
Elsevier Masson SAS. Tous droits réservés.
Article précédent
